Metastasiertes kolorektales Karzinom

详细信息    查看全文

• 作者：T.J. Ettrich ; Prof. Dr. T. Seufferlein
• 关键词：Kolorektales Karzinom ; Metastasen ; Systemtherapie ; RAS ; Gen ; mKRK ; Colorectal cancer ; Metastases ; Systemic chemotherapy ; RAS gene ; mCRC
• 刊名：Der Onkologe
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：22
• 期：2
• 页码：109-114
• 全文大小：172 KB
• 参考文献：1.Atreya CE, Van Cutsem E, Bendell JC et al (2015) Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 33 (Suppl; Abstract 103)
  2.Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37CrossRef PubMed
  3.Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488CrossRef PubMed
  4.Cunningham D, Lang I, Marcuello E et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077–1085CrossRef PubMed
  5.Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712CrossRef
  6.Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034CrossRef PubMed
  7.Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544CrossRef PubMed
  8.Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312CrossRef PubMed
  9.Hegewisch-Becker S, Graeven U, Lerchenmuller CA et al (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16(13):1355–1369CrossRef PubMed
  10.Heinemann V, Weikersthal LF von, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075CrossRef PubMed
  11.Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65CrossRef PubMed
  12.Kohne CH (2009) Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol 27:15sCrossRef
  13.Le DT, Uram JN, Wang H et al (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372:2509–2520CrossRef PubMed
  14.Lenz H, Niedzwiecki D, Innocenti F et al (2014) CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Onc 25(5):1–41. doi:10.1093/annonc/mdu438CrossRef
  15.Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609–1618CrossRef PubMed
  16.Loupakis F, Cremolini C, Salvatore L et al (2014) FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50:57–63CrossRef PubMed
  17.Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919CrossRef PubMed
  18.Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713CrossRef PubMed
  19.Preto A, Figueiredo J, Velho S et al (2008) BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 214:320–327CrossRef PubMed
  20.Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRef PubMed
  21.Schwartzberg LS, Rivera F, Karthaus M et al (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240–2247CrossRef PubMed
  22.Siena S, Sartore-Bianchi A, Lonardi S et al (2015) Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial. J Clin Oncol 33 (Suppl 3; Abstract 565)
  23.Simkens LH, Tinteren H van, May A et al (2015) Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet pii:S0140-6736(14)62004-3
  24.Stinzing S (2013) Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress 2013 Amsterdam
  25.Tabernero J, Van Cutsem E, Lakomy R et al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50:320–331CrossRef PubMed
  26.Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499–508CrossRef PubMed
  
• 作者单位：T.J. Ettrich (1)
  Prof. Dr. T. Seufferlein (1)
  
  1. Klinik für Innere Medizin I, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0415

文摘

Background Colorectal cancer (CRC) is the third leading cause of cancer deaths worldwide. In recent years overall survival, particularly in the metastatic setting, could be substantially prolonged. This is not least due to novel options for systemic treatment of metastatic CRC (mCRC). A major contribution to this development came from the increasing understanding of genetic and epigenetic dysregulation in CRC that lead to dysregulated signaling networks in tumors and subsequently to dysregulated cell survival, tumor growth and metastasis. Various strategies have been developed to selectively disrupt vital signaling networks of tumors and novel targeted drugs have a major effect on the tumor and (ideally) only minimal adverse drug reactions (targeted therapies).